The Oncology Institute, Inc. (STLN) fair value analysis
Nasdaq · Updated 2026-10-19
STLN price how computed
Valuation status
No fair-value estimate yetSTLN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for STLN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $6.43
- Sector
- Healthcare
- 12-month range
- $2.38–$7.05
- Market cap
- $655M
- From 52-week high
- -8.8%
- Shares outstanding
- 102M
- Rank in Healthcare by quality score
- #281 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
The Oncology Institute, Inc. is a healthcare company that provides cancer treatment and oncology services to patients. The company operates multiple treatment centers and facilities across the United States.
STLN currently ranks #281 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $655M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $587M
- Net margin
- -6.2%
- EPS (TTM)
- $-0.30
- Gross margin
- 16.8%
- Debt / equity
- 0.00
- Shares outstanding
- 102M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 47 · neutral
- 50-day average
- $6.42
- 200-day average
- $4.56
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 5 quarters vs consensus
- 2 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-14.3%)
2026-03 ▲ beat (+77.1%)
2025-12 ▲ beat (+33.3%)
2025-09 ▼ miss (-23.6%)
2025-06 ▼ miss (-25.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $9.4
- Target vs last price
- +46.2%
What our data shows for STLN
- Shares are trading in the upper third of their 12-month price range of $2.38–$7.05.
- The 14-day relative strength index sits at a neutral 47.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- STLN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the STLN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is STLN stock undervalued?
TickrTrends has no fair-value estimate for STLN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is STLN's TickrTrends verdict?
STLN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does STLN compare to other Healthcare stocks?
STLN ranks #281 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is STLN overbought or oversold?
STLN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does STLN report earnings next?
STLN's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does STLN usually beat earnings estimates?
Over its last 5 reported quarters STLN beat the consensus estimate 2 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about STLN?
Of 5 analysts covering STLN, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $9.4 (+46.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.